iClusig (™) (ponatinib)


ICLUSIG ™ (Ponatinib) is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML or Ph+ALL that is T315I mutation positive or where there is prior TKI resistance or intolerance.

To read the announcement from Ariad regarding the approval from Health Canada for iClusig (TM): iClusig (TM) N.O.C.

Comments are closed .